91 related articles for article (PubMed ID: 2991397)
21. [Clinical investigation of serum immunosuppressive acidic protein (IAP) in patients with gastric cancer].
Kageyama T; Oyabu H; Ohshiba S
Gan No Rinsho; 1986 Sep; 32(11):1416-20. PubMed ID: 3773269
[TBL] [Abstract][Full Text] [Related]
22. [Serum CA125 in malignant ovarian tumor--periodical monitoring and correlation with other tumor markers].
Kawai M; Yamashita H; Hayashi T; Kamiya N; Kakihara M; Arii Y
Nihon Sanka Fujinka Gakkai Zasshi; 1986 Mar; 38(3):402-10. PubMed ID: 3457877
[TBL] [Abstract][Full Text] [Related]
23. [Clinical value of a new serum tumor marker CA602 in ovarian cancers].
Suzuki M; Sekiguchi I; Ohwada M; Aida I; Tamada T
Nihon Gan Chiryo Gakkai Shi; 1990 Jul; 25(7):1454-60. PubMed ID: 2170549
[TBL] [Abstract][Full Text] [Related]
24. [Urine levels of immunosuppressive acidic protein in patients with or without cancer].
Hirayama T
Nihon Geka Gakkai Zasshi; 1985 Oct; 86(10):1379-87. PubMed ID: 4079895
[TBL] [Abstract][Full Text] [Related]
25. [Clinical evaluation of the serum level of immunosuppressive acidic protein (IAP) and immunosuppressive substance (IS) in gastric cancer patients].
Sakita M; Yamane T; Kasuga M; Torii T; Imai H; Kageyama N; Fujita Y; Majima S
Gan To Kagaku Ryoho; 1982 Oct; 9(10):1755-64. PubMed ID: 7184372
[TBL] [Abstract][Full Text] [Related]
26. Immunosuppressive acidic protein (IAP) and squamous cell carcinoma antigen (SCC) in patients with cervical cancer.
Battaglia F; Scambia G; Panici PB; Castelli M; Ferrandina G; Foti E; Amoroso M; D'Andrea G; Mancuso S
Gynecol Oncol; 1994 May; 53(2):176-82. PubMed ID: 8188076
[TBL] [Abstract][Full Text] [Related]
27. Is there a correlation between tumor marker panel and tumor size and histopathology in well staged patients with borderline ovarian tumors?
Ayhan A; Guven S; Guven ES; Kucukali T
Acta Obstet Gynecol Scand; 2007; 86(4):484-90. PubMed ID: 17486473
[TBL] [Abstract][Full Text] [Related]
28. [Immunosuppressive acidic protein (IAP) and immunosuppressive substance (ISS) in patients with renal cell carcinoma].
Yamazaki K; Kumamoto Y; Tsukamoto T; Ohmura K; Miyao N; Yoshioka M; Iwasawa A
Hinyokika Kiyo; 1991 May; 37(5):467-74. PubMed ID: 1858580
[TBL] [Abstract][Full Text] [Related]
29. [Study on serum vascular endothelial growth factor level in ovarian malignant tumors].
Li L; Wang LM; Zhang W; Zhang JQ; Song HL; Yao DS; Tang Y; Chen XQ; Yang ZH
Zhonghua Fu Chan Ke Za Zhi; 2003 Feb; 38(2):72-6. PubMed ID: 12783691
[TBL] [Abstract][Full Text] [Related]
30. [The clinical significance of CA125 in patients with gynecological tumors--a comparative study on CA125 and other tumor markers].
Suzumori K; Yasui Y; Asai H; Hisaoka T; Mizuno K; Yagami Y
Gan No Rinsho; 1985 May; 31(5):544-8. PubMed ID: 3860666
[TBL] [Abstract][Full Text] [Related]
31. Clinical usefulness of sialyl SSEA-1 antigen as tumor marker for ovarian cancer as compared with CA125, CA19-9, TPA, IAP, CEA and ferritin.
Yabushita H; Sawaguchi K; Hieda S; Ogawa A; Tomatsu A; Noguchi M; Ishihara M
Nihon Sanka Fujinka Gakkai Zasshi; 1989 Feb; 41(2):217-24. PubMed ID: 2566639
[TBL] [Abstract][Full Text] [Related]
32. [Inflammatory reaction and laboratory tests: IAP (immunosuppressive acidic protein)].
Sato T; Sakata Y; Tamura K
Rinsho Byori; 1990 Mar; 38(3):255-9. PubMed ID: 2190023
[TBL] [Abstract][Full Text] [Related]
33. [Clinical evaluation of serum immunosuppressive acidic protein (IAP) and acid soluble glycoproteins (ASP) in patients with malignant tumors].
Shibasaki K; Soga K; Toshima M; Aikawa K; Tsuruya T; Itoh T; Takahashi Y; Tsuchimochi M; Mataga I; Tsuchikawa K
Shigaku; 1989 Aug; 77(2):701-11. PubMed ID: 2489324
[TBL] [Abstract][Full Text] [Related]
34. Accuracy of tissue polypeptide specific antigen (TPS) in the diagnosis of ovarian malignancy.
Padungsutt P; Thirapagawong C; Senapad S; Suphanit I
Anticancer Res; 2000; 20(2B):1291-5. PubMed ID: 10810437
[TBL] [Abstract][Full Text] [Related]
35. [An evaluation of carcinoembryonic antigen (CEA), beta 2-microglobulin (BMG), and immunosuppressive acidic protein (IAP) in the serum of primary lung cancer patients].
Higuchi Y
Gan No Rinsho; 1986 Jan; 32(1):33-40. PubMed ID: 3005690
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of immunosuppressive acidic protein in human ovarian cancer.
Lin YH; Chow SN; Chen CK; Chen RJ; Huang SC; Huang GT
J Formos Med Assoc; 1994 Sep; 93(9):776-80. PubMed ID: 7735007
[TBL] [Abstract][Full Text] [Related]
37. Serum immunosuppressive acidic protein doubling time as a prognostic factor for recurrent renal cell carcinoma after nephrectomy.
Araki K; Igarashi T; Tobe T; Mizoguchi K; Suzuki H; Furuya Y; Ichikawa T; Nakatsu HO; Ito H
Urology; 2006 Dec; 68(6):1178-82. PubMed ID: 17141843
[TBL] [Abstract][Full Text] [Related]
38. Serum C-reactive protein in the differential diagnosis of ovarian masses.
Hefler-Frischmuth K; Hefler LA; Heinze G; Paseka V; Grimm C; Tempfer CB
Eur J Obstet Gynecol Reprod Biol; 2009 Nov; 147(1):65-8. PubMed ID: 19619929
[TBL] [Abstract][Full Text] [Related]
39. Simultaneous measurement of CA 125, CA 19-9, tissue polypeptide antigen, and immunosuppressive acidic protein to predict recurrence of ovarian cancer.
Kamiya N; Mizuno K; Kawai M; Kano T; Furuhashi Y; Tomoda Y
Obstet Gynecol; 1990 Sep; 76(3 Pt 1):417-21. PubMed ID: 2381619
[TBL] [Abstract][Full Text] [Related]
40. [Relationship between tumor markers and clinical symptoms in ovarian cancer].
Yakushiji M; Nishimura H
Rinsho Byori; 1992 Apr; 40(4):354-8. PubMed ID: 1593760
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
